Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Other Accumulated Expenses (2023 - 2025)

Historic Other Accumulated Expenses for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $1.2 million.

  • Contineum Therapeutics' Other Accumulated Expenses fell 1253.73% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 1253.73%. This contributed to the annual value of $3.2 million for FY2024, which is 10381.63% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Other Accumulated Expenses of $1.2 million as of Q3 2025, which was down 1253.73% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Other Accumulated Expenses registered a high of $3.2 million during Q4 2024, and its lowest value of $973000.0 during Q2 2024.
  • Over the past 3 years, Contineum Therapeutics' median Other Accumulated Expenses value was $1.6 million (recorded in 2023), while the average stood at $1.8 million.
  • Per our database at Business Quant, Contineum Therapeutics' Other Accumulated Expenses soared by 10381.63% in 2024 and then crashed by 1253.73% in 2025.
  • Quarter analysis of 3 years shows Contineum Therapeutics' Other Accumulated Expenses stood at $1.5 million in 2023, then skyrocketed by 103.82% to $3.2 million in 2024, then plummeted by 62.81% to $1.2 million in 2025.
  • Its Other Accumulated Expenses was $1.2 million in Q3 2025, compared to $1.7 million in Q2 2025 and $2.5 million in Q1 2025.